NZ536513A - Use of EDG receptor binding agents in cancer - Google Patents

Use of EDG receptor binding agents in cancer

Info

Publication number
NZ536513A
NZ536513A NZ536513A NZ53651303A NZ536513A NZ 536513 A NZ536513 A NZ 536513A NZ 536513 A NZ536513 A NZ 536513A NZ 53651303 A NZ53651303 A NZ 53651303A NZ 536513 A NZ536513 A NZ 536513A
Authority
NZ
New Zealand
Prior art keywords
compound
inhibitor
formula
alkyl
phenyl
Prior art date
Application number
NZ536513A
Other languages
English (en)
Inventor
Thomas Baumruker
Volker Brinkmann
Montagne Kenneth Richard La
Peter T Lassota
Diana Mechtcheriakova
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211261A external-priority patent/GB0211261D0/en
Priority claimed from GB0217150A external-priority patent/GB0217150D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ536513A publication Critical patent/NZ536513A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ536513A 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer NZ536513A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds
US39041102P 2002-06-20 2002-06-20
GB0217150A GB0217150D0 (en) 2002-07-24 2002-07-24 Organic compounds
US44973903P 2003-02-24 2003-02-24
PCT/EP2003/005125 WO2003097028A1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer

Publications (1)

Publication Number Publication Date
NZ536513A true NZ536513A (en) 2007-10-26

Family

ID=29554311

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ560662A NZ560662A (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
NZ536513A NZ536513A (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ560662A NZ560662A (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer

Country Status (22)

Country Link
US (2) US20090209495A1 (enExample)
EP (3) EP1944026B1 (enExample)
JP (3) JP5227492B2 (enExample)
KR (1) KR20120125398A (enExample)
CN (1) CN1652757B (enExample)
AT (1) ATE412408T1 (enExample)
AU (1) AU2003240655B2 (enExample)
BR (1) BR0311173A (enExample)
CA (1) CA2483594C (enExample)
CY (1) CY1108719T1 (enExample)
DE (1) DE60324416D1 (enExample)
DK (1) DK1505959T3 (enExample)
ES (1) ES2316758T3 (enExample)
IL (3) IL164838A (enExample)
MX (1) MXPA04011384A (enExample)
NO (2) NO334074B1 (enExample)
NZ (2) NZ560662A (enExample)
PL (1) PL372103A1 (enExample)
PT (1) PT1505959E (enExample)
SI (1) SI1505959T1 (enExample)
WO (1) WO2003097028A1 (enExample)
ZA (1) ZA200408575B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
ATE435202T1 (de) 2002-01-11 2009-07-15 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
WO2003104442A1 (en) 2002-06-07 2003-12-18 Es Cell International Pte Ltd Methods of regulating differentiation in stem cells
AU2004213297B2 (en) * 2003-02-18 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
JP2008509931A (ja) 2004-08-13 2008-04-03 プレーシス ファーマスーティカルズ インコーポレイテッド スフィンゴシン−１−ホスフェート（ｓ１ｐ）レセプター活性を調節するための方法および組成物
AU2005325227B2 (en) * 2004-10-28 2012-11-01 Lpath Therapeutics, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
JP5035752B2 (ja) 2006-02-03 2012-09-26 大正製薬株式会社 トリアゾール誘導体
WO2007091570A1 (ja) 2006-02-06 2007-08-16 Taisho Pharmaceutical Co., Ltd. スフィンゴシン－１－リン酸結合阻害物質
AU2007234380A1 (en) * 2006-04-06 2007-10-11 Novartis Ag Combination of organic compounds
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US8048898B2 (en) 2007-08-01 2011-11-01 Taisho Pharmaceutical Co., Ltd Inhibitor of binding of S1P1
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
MX2011004924A (es) * 2008-11-11 2011-05-30 Novartis Ag Sales de fingolimod.
AU2009315736B2 (en) * 2008-11-11 2013-08-29 Novartis Ag Crystalline forms of fingolimod HCL
IL294658A (en) 2008-12-22 2022-09-01 Novartis Ag Dosage regimen of an s1p receptor agonist
SG171404A1 (en) 2008-12-22 2011-07-28 Novartis Ag Dosage regimen for a s1p receptor agonist
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
KR20120032538A (ko) 2009-07-24 2012-04-05 라티오팜 게엠베하 핀골리모드 염의 제조 방법
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
SG10201406168RA (en) 2009-09-29 2014-11-27 Novartis Ag Dosage regimen of an s1p receptor modulator
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
JO3619B1 (ar) 2011-01-07 2020-08-27 Novartis Ag صياغات مثبطة للمناعة
MY163274A (en) 2011-02-07 2017-08-30 Biogen Ma Inc S1p modulating agents
SG11201401065RA (en) 2011-10-21 2014-09-26 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
JP6033791B2 (ja) * 2011-12-23 2016-11-30 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｓ１ｐ受容体調整薬
HK1211237A1 (en) 2012-08-06 2016-05-20 Biogen Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents
EP2879673B1 (en) 2012-08-06 2018-07-25 Biogen MA Inc. 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders
WO2014081752A1 (en) 2012-11-20 2014-05-30 Biogen Idec Ma Inc. S1p and/or atx modulating agents
ES2749467T3 (es) 2012-11-20 2020-03-20 Biogen Ma Inc Agentes moduladores de S1p y/o ATX
CN105026360B (zh) 2013-01-29 2017-08-25 比奥根Ma公司 S1p调节剂
US20160039825A1 (en) 2013-03-15 2016-02-11 Biogen Ma Inc. S1p and/or atx modulating agents
CN103417970A (zh) * 2013-08-15 2013-12-04 泰山医学院 雌激素上调内皮系统保护分子鞘氨醇1-磷酸的应用
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3443986A1 (en) 2017-08-17 2019-02-20 AC BioScience Enhancement of chemotherapy efficiency by sphingosine-1-phosphate

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36730A0 (en) * 1970-05-28 1971-06-23 Chemagro Corp Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DK0627406T3 (da) * 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ES2146741T3 (es) 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
EP0954315A2 (en) 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
DK1319651T3 (da) * 1997-04-04 2005-08-01 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
EP1070080A4 (en) * 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
CA2355976C (en) 1998-12-22 2012-07-17 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
SK152003A3 (en) 2000-07-13 2004-07-07 Sankyo Co Amino alcohol derivatives
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
AU2002235175A1 (en) * 2000-12-06 2002-06-18 Tularik, Inc. Lometrexol combination therapy
PL367348A1 (en) 2001-03-26 2005-02-21 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
JP4217620B2 (ja) 2001-09-27 2009-02-04 杏林製薬株式会社 ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤

Also Published As

Publication number Publication date
AU2003240655B2 (en) 2007-09-06
US20090209495A1 (en) 2009-08-20
NZ560662A (en) 2009-09-25
US20140303257A1 (en) 2014-10-09
JP2005529921A (ja) 2005-10-06
IL164838A (en) 2013-12-31
JP2010100637A (ja) 2010-05-06
HK1126127A1 (en) 2009-08-28
ATE412408T1 (de) 2008-11-15
EP1944026A3 (en) 2011-06-01
BR0311173A (pt) 2005-03-15
IL164838A0 (en) 2005-12-18
IL229559A0 (en) 2014-01-30
EP1505959A1 (en) 2005-02-16
CN1652757A (zh) 2005-08-10
NO334074B1 (no) 2013-12-02
EP1944026B1 (en) 2013-06-26
CN1652757B (zh) 2012-02-08
HK1073606A1 (en) 2005-10-14
SI1505959T1 (sl) 2009-04-30
EP1955696A3 (en) 2011-05-25
JP2013136584A (ja) 2013-07-11
DE60324416D1 (de) 2008-12-11
EP1505959B1 (en) 2008-10-29
AU2003240655A1 (en) 2003-12-02
EP1955696B1 (en) 2014-05-28
PL372103A1 (en) 2005-07-11
PT1505959E (pt) 2009-02-05
NO20130106L (no) 2004-12-03
CY1108719T1 (el) 2014-04-09
CA2483594C (en) 2011-02-15
JP5227492B2 (ja) 2013-07-03
WO2003097028A1 (en) 2003-11-27
IL229550A0 (en) 2014-01-30
CA2483594A1 (en) 2003-11-27
EP1944026A2 (en) 2008-07-16
NO20045312L (no) 2004-12-03
ES2316758T3 (es) 2009-04-16
KR20120125398A (ko) 2012-11-14
EP1955696A2 (en) 2008-08-13
MXPA04011384A (es) 2005-02-14
ZA200408575B (en) 2005-07-27
DK1505959T3 (da) 2009-02-23

Similar Documents

Publication Publication Date Title
EP1944026B1 (en) Use of EDG receptor binding agents in cancer
JP6383814B2 (ja) 癌の処置
US20050215531A1 (en) Use of edg receptor binding agents in cancer
RU2426555C2 (ru) Применение средств, связывающих edg-рецептор, в лечении ракового заболевания
AU2007237378B2 (en) Use of EDG receptor binding agents in cancer
AU2011205049B2 (en) Use of EDG receptor binding agents in cancer
ES2428697T3 (es) Uso de agentes de enlace del receptor EDG en el cáncer
CN101305990B (zh) Edg受体结合剂在癌症中的应用
HK1073606B (en) Use of edg receptor binding agents in cancer
HK1126127B (en) Use of edg receptor binding agents in cancer

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 MAY 2016 BY CPA GLOBAL

Effective date: 20130405

LAPS Patent lapsed